Scholarlink

Background <p>Optimal triage option for high-risk HPV-positive (hrHPV) women remains uncertain. We aimed to utilize methylation-sensitive restriction enzyme-based quantitative PCR (MSRE-qPCR) technique and develop triple-target human gene methylation panels to improve detection of advanced cervical precancers and cancers (CIN3 +) among hrHPV women.</p> Methods <p>Eighteen candidate genes were detected by MSRE-qPCR in cervical samples from hrHPV women. All possible triple-target panels from these genes were generated by logistic regression models with repeated ten-fold cross-validation on a training set of 1223 women (180 CIN3 +; 1043 &lt; CIN3). Panels with the top two AUCs for CIN3 + on a validation set of 937 women (69 CIN3 +; 868 &lt; CIN3) were ultimately selected for qPCR reconstruction, retesting, and retraining. Triage performance, screening efficiency and risk stratification of the selected panels were then compared with traditional triage strategies (cytology [ASCUS as the threshold, atypical squamous cells of undetermined significance], HPV16/18 genotyping, HPV16/18 genotyping combined with cytology [ASCUS]) within the validation set.</p> Results <p>Two panels were finally identified and validated for CIN3 + detection. Panel 1 includes <i>JAM3</i>, <i>PCDHGB7</i>, and <i>SORCS1</i>; while Panel 2 consists of <i>PAX1</i>, <i>ZNF671</i>, and <i>ASCL1</i>. Compared to traditional triage strategies, both panels demonstrated superior AUCs (Panel 1: 0.799; Panel 2: 0.790; Cytology: 0.532; HPV16/18 genotyping: 0.589; HPV16/18 + Cytology: 0.515; all <i>P</i><sub>AUC</sub> &lt; 0.001), with substantially higher specificities (83.06%; 86.98%; 29.49%; 72.93%; 14.52%), comparable sensitivities (76.81%; 71.01%; 76.81%; 44.93%; 88.41%), and requiring fewer colposcopies per CIN3 + case (3.77; 3.31; 12.55; 8.58; 13.16). However, Panel 1 and Panel 2 were statistically indistinguishable (<i>P</i><sub>AUC</sub> = 0.603; Ratio<sub>sensitivity</sub>: 0.92 [0.76–1.13]; Ratio<sub>specificity</sub>: 1.05 [1.01–1.08]). Unlike traditional strategies (CIN3 + risks: 5.59% ~ 17.97%), women tested negative on either panel had immediate CIN3 + risks below 3% (Panel 1: 2.17%; Panel 2: 2.58%), supporting safe deferral for at least one year.</p> Conclusions <p>Two triple-target human gene methylation panels were successfully developed, each integrated into a single MSRE-qPCR system for one-tube detection. Both panels outperformed current triage strategies, indicating their potential as alternatives, though external validation among diverse settings is needed before clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel triple-target panels utilizing methylation-sensitive restriction enzyme-based quantitative PCR for detecting advanced cervical precancers and cancers among high-risk HPV-positive women

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月1日

查看全文
  • Shimin Chen,
  • Hongshuang Dai,
  • Shangying Hu,
  • Tangjie Gao,
  • Ming Chen,
  • Xinghua Zhou,
  • Lizhong Dai,
  • Xuelian Zhao,
  • Fanghui Zhao

摘要

Background

Optimal triage option for high-risk HPV-positive (hrHPV) women remains uncertain. We aimed to utilize methylation-sensitive restriction enzyme-based quantitative PCR (MSRE-qPCR) technique and develop triple-target human gene methylation panels to improve detection of advanced cervical precancers and cancers (CIN3 +) among hrHPV women.

Methods

Eighteen candidate genes were detected by MSRE-qPCR in cervical samples from hrHPV women. All possible triple-target panels from these genes were generated by logistic regression models with repeated ten-fold cross-validation on a training set of 1223 women (180 CIN3 +; 1043 < CIN3). Panels with the top two AUCs for CIN3 + on a validation set of 937 women (69 CIN3 +; 868 < CIN3) were ultimately selected for qPCR reconstruction, retesting, and retraining. Triage performance, screening efficiency and risk stratification of the selected panels were then compared with traditional triage strategies (cytology [ASCUS as the threshold, atypical squamous cells of undetermined significance], HPV16/18 genotyping, HPV16/18 genotyping combined with cytology [ASCUS]) within the validation set.

Results

Two panels were finally identified and validated for CIN3 + detection. Panel 1 includes JAM3, PCDHGB7, and SORCS1; while Panel 2 consists of PAX1, ZNF671, and ASCL1. Compared to traditional triage strategies, both panels demonstrated superior AUCs (Panel 1: 0.799; Panel 2: 0.790; Cytology: 0.532; HPV16/18 genotyping: 0.589; HPV16/18 + Cytology: 0.515; all PAUC < 0.001), with substantially higher specificities (83.06%; 86.98%; 29.49%; 72.93%; 14.52%), comparable sensitivities (76.81%; 71.01%; 76.81%; 44.93%; 88.41%), and requiring fewer colposcopies per CIN3 + case (3.77; 3.31; 12.55; 8.58; 13.16). However, Panel 1 and Panel 2 were statistically indistinguishable (PAUC = 0.603; Ratiosensitivity: 0.92 [0.76–1.13]; Ratiospecificity: 1.05 [1.01–1.08]). Unlike traditional strategies (CIN3 + risks: 5.59% ~ 17.97%), women tested negative on either panel had immediate CIN3 + risks below 3% (Panel 1: 2.17%; Panel 2: 2.58%), supporting safe deferral for at least one year.

Conclusions

Two triple-target human gene methylation panels were successfully developed, each integrated into a single MSRE-qPCR system for one-tube detection. Both panels outperformed current triage strategies, indicating their potential as alternatives, though external validation among diverse settings is needed before clinical application.